Ipilimumab

證據等級: L5

預測適應症: 2 個

Ipilimumab: From Cutaneous Melanoma to Non-Cutaneous Melanoma

One-Sentence Summary

Ipilimumab is an anti-CTLA-4 immune checkpoint inhibitor originally established for (cutaneous) metastatic melanoma. The TxGNN model additionally predicts activity in Non-Cutaneous Melanoma (uveal, mucosal, acral, and CNS-metastatic subtypes), with 80 clinical trials and 5 publications identified in the evidence pack, including several completed Phase 2/3 studies specific to non-cutaneous subtypes.

Note: The evidence pack also contained a second TxGNN prediction — choroideremia (score 99.06%, rank 9029) — but this candidate has zero supporting trials or literature, and the pack itself states there is no known mechanistic link between anti-CTLA-4 immune activation and this monogenic retinal degeneration. It has been screened out (evidence level L5, decision stage S0, recommendation Hold) and is not discussed further below.

Quick Overview

Item	Content
Original Indication	Metastatic (cutaneous) melanoma — no local license on file (see note below)
Predicted New Indication	Non-Cutaneous Melanoma (uveal, mucosal, acral, leptomeningeal-metastatic)
TxGNN Prediction Score	99.02%
Evidence Level	L2
Norway Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Ipilimumab is an anti-CTLA-4 monoclonal antibody. It blocks the inhibitory CTLA-4 signal on T cells, thereby restoring and amplifying tumor-specific T-cell activation and proliferation. Critically, this is a host immune-modulation mechanism, not one that targets a specific tumor genotype (e.g., BRAF mutation status). Because the drug acts on the patient's immune system rather than on melanoma-specific molecular drivers, there is a plausible mechanistic rationale for activity across melanoma subtypes beyond the cutaneous form — including uveal, mucosal, acral, and CNS-metastatic (leptomeningeal) disease.

Ipilimumab is already established for metastatic cutaneous melanoma. The predicted new indication, non-cutaneous melanoma, represents a label-adjacent extension within the same disease family rather than a novel therapeutic area — a pattern generally associated with lower repurposing risk. That said, the rationale in the evidence pack flags an important caveat: uveal melanoma occurs in an immune-privileged ocular environment and typically carries a lower tumor mutational burden, and mucosal melanoma shows a similar, though less pronounced, pattern. Both subtypes have historically shown lower response rates to checkpoint inhibition than cutaneous disease, which tempers — but does not eliminate — the mechanistic plausibility.

Detailed drug-level mechanism-of-action documentation (DrugBank MOA field) was not available in this evidence pack; the mechanistic description above is derived from the repurposing rationale rather than a structured MOA record.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01654692	Phase 2	Completed	86	Ipilimumab + fotemustine in unresectable/locally advanced or metastatic melanoma, including uveal melanoma population — direct, completed evidence (Grade A)
NCT02626962	Phase 2	Completed	52	Nivolumab + ipilimumab in previously untreated metastatic uveal melanoma — directly relevant non-cutaneous subtype
NCT01730157	Early Phase 1	Terminated	6	Sequential hepatic radioembolization + ipilimumab in uveal melanoma with liver metastases
NCT02939300	Phase 2	Completed	18	Ipilimumab + nivolumab in melanoma leptomeningeal metastases (Grade B)
NCT03220009	Phase 2	Withdrawn	0	Adjuvant nivolumab vs. observation after neoadjuvant ipilimumab+nivolumab in mucosal melanoma — directly relevant subtype but trial withdrawn
NCT02224781	Phase 3	Active, not recruiting	267	DREAMseq: sequencing of ipilimumab+nivolumab vs. targeted therapy in advanced melanoma (Grade B, indirect support)
NCT01927419	Phase 2	Completed	142	Randomized double-blind nivolumab+ipilimumab vs. ipilimumab alone in untreated advanced melanoma (Grade B, indirect support)
NCT01810016	Phase 1	Terminated	8	NY-ESO-1 vaccine + ipilimumab in unresectable/metastatic melanoma (Grade C, weak evidence)
NCT02388906	Phase 3	Completed	906	CheckMate 238: adjuvant nivolumab vs. ipilimumab after resection of high-risk melanoma — large completed RCT, general population
NCT01515189	Phase 3	Completed	831	Ipilimumab 3 mg/kg vs. 10 mg/kg in previously treated/untreated melanoma — large completed dose-finding RCT, general population

Literature Evidence

PMID	Year	Type	Journal	Key Findings
24999899	2014	Cohort	The Medical Journal of Australia	Real-world efficacy/tolerability of ipilimumab across cutaneous, uveal, and mucosal melanoma; assessed response by subtype, BRAF status, and irAE incidence
28183255	2018	Review	Current Cancer Drug Targets	Systematic review of melanoma adjuvant treatment (2000–2015); explicitly notes non-cutaneous melanoma comprises ~5% of cases
37887546	2023	Cohort	Current Oncology	Retrospective multicenter cohort comparing anti-PD-1 monotherapy vs. combination with ipilimumab by age group in advanced melanoma
29466692	2018	Review	Discovery Medicine	Clinical update on anti-PD-1 antibodies as monotherapy or combined with ipilimumab in advanced melanoma
40236344	2025	Case Report	Cureus	Case of metastatic melanoma with colonic involvement, treated with immunotherapy; highlights GI immune-related adverse event risk

Norway Market Information

Ipilimumab is not currently marketed in this jurisdiction (0 authorizations on file). No local license records or approved indication text are available for extraction.

Cytotoxicity

Melanoma is a malignant neoplasm, and ipilimumab is an anticancer immune checkpoint inhibitor; this section is included per the antineoplastic-drug criteria.

Item	Content
Cytotoxicity Classification	Immunotherapy (anti-CTLA-4 immune checkpoint inhibitor)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Note: Unlike conventional cytotoxic chemotherapy, checkpoint inhibitors are primarily associated with immune-related adverse events (e.g., colitis, hepatitis, dermatitis, endocrinopathies) rather than myelosuppression — but no drug-specific toxicity data were present in this evidence pack, so specific claims are deferred to the package insert.

Safety Considerations

Please refer to the package insert for safety information. No warnings, contraindications, or drug-interaction data were available in this evidence pack — this is flagged as a Blocking data gap (DG001: TFDA/local label warnings and contraindications) that must be resolved before this candidate can proceed to safety evaluation (S1).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple completed Phase 2 trials provide direct evidence for ipilimumab activity in non-cutaneous melanoma subtypes (uveal, mucosal, leptomeningeal-metastatic), and the mechanism — non-genotype-specific immune activation — is plausibly generalizable across melanoma subtypes. However, response rates in uveal and mucosal disease are historically lower than in cutaneous melanoma, and the drug is not currently marketed in this jurisdiction, so evidence is sufficient to advance cautiously but not for an unconditional Go.

To proceed, the following is needed:

Local label safety data (TFDA/regulatory warnings, contraindications) — currently a Blocking gap (DG001)
Structured mechanism-of-action documentation from DrugBank (DG002)
Subtype-stratified efficacy data (uveal vs. mucosal vs. acral response rates) to size expected benefit
Route/formulation compatibility assessment (currently pending in evidence pack)
Market entry/registration pathway assessment, since the drug currently holds zero local authorizations
Exclude choroideremia from further development given absence of mechanistic plausibility and supporting evidence
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.